Ventricular assist devices in the adult

Critical Care Nursing Quarterly

Volumn 30, Issue 2, 2007, Pages 104-118

  Richards, Nancy M ^a   Stahl, Mary A ^a  

^a ST LUKE S HOSPITAL   (United States)

Author keywords

Congestive heart failure; Heart assist devices; Ventricular assist devices

Indexed keywords

ASSISTED CIRCULATION; BLEEDING; CARDIAC PATIENT; CARDIOPULMONARY BYPASS; COST; DEVICE INFECTION; HEART ASSIST DEVICE; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HEART TAMPONADE; HEART TRANSPLANTATION; HUMAN; MEDICAL ETHICS; PULSATILE FLOW; REVIEW; THORAX SURGERY; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; ADULT; BIOMEDICAL TECHNOLOGY ASSESSMENT; CASE REPORT; CONGESTIVE HEART FAILURE; CROSS INFECTION; ECONOMICS; EMERGENCY; EQUIPMENT; EQUIPMENT DESIGN; ETHICS; FORWARD HEART FAILURE; HEART RIGHT VENTRICLE FUNCTION; HOSPITAL ADMISSION; INTENSIVE CARE; MALE; METHODOLOGY; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; PATIENT SELECTION; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; RISK FACTOR;

ADULT; CARDIAC OUTPUT, LOW; CARDIAC TAMPONADE; CRITICAL CARE; CROSS INFECTION; EMERGENCIES; EQUIPMENT DESIGN; EQUIPMENT FAILURE; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; MALE; NURSE'S ROLE; NURSING ASSESSMENT; PATIENT SELECTION; PERIOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; RISK FACTORS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; THROMBOEMBOLISM; VENTRICULAR DYSFUNCTION, RIGHT; WAITING LISTS;

EID: 34249748011     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CNQ.0000264254.90499.27     Document Type: Review

References (43)

1. Frazier OH, Rose EA, Oz MC, et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg. 2001;122:1186-1195.
2. American Heart Association. Heart Disease and Stroke Statistics: 2006 Update. Dallas, Tex: American Heart Association; 2004. Available at: www.americanheart.org. Accessed July 24, 2006.
3. Rose EA, Gelijns AC, Moskowitz AJ, et al, for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345:1435-1443.
4. Lietz K, Miller LW. Left ventricular assist devices: evolving devices and indications for use in ischemic heart disease. Curr Opin Cardiol. 2004;19:613-618.
5. Delgado RM, Bergheim M. Management of acute and chronic heart failure with left ventricular assist devices. Am Heart Hosp J. 2005;3:153-160.
6. Aragon J, Lee MS, Kar S, Makkar RR. Percutaneous left ventricular assist device: "TandemHeart"for high-risk coronary intervention. Catheter Cardiovasc Interv. 2005;65:346-352.
7. DeBakey ME. Left ventricular bypass pump for cardiac assistance. Clinical experience. Am J Cardiol. 1971;27:3-11.
8. Marik PE, Zaloga GP. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med. 2001;29:2264-2270.
9. Clement S, Braithwaite SS, Magee ME, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27:553-597.
10. Shinn JA. Implantable left ventricular devices. J Cardiovasc Nurs. 2005;20:522-530.
11. Ochiai Y, McCarthy PM, Smedira NG, et al. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation. 2002;106(12 suppl 1): I198-I202.
12. Delgado R, Frazier OH, Meyers TJ, et al. Direct thrombolytic therapy for intraventricular thrombosis in patients with the Jarvik 2000 left ventricular assist device. J Heart Lung Transplant. 2005;24:231-233.
13. Chinn R, DembitskyW, Eaton L, et al. Multicenter experience: prevention and management of left ventricular assist device infections. ASAIO J. 2005;51:461-470.
14. Baudouin S, Evans, T. Nutrition support in critical care. Available at: http://www.Mdconsult.com. Accessed July 24, 2006.
15. Horton SC, Khodaverdian R, Powers A, et al. Left ventricular assist device malfunction: a systematic approach to diagnosis. J Am Coll Cardiol. 2004;43:1574-1583.
16. Horton SC, Khodaverdian R, Chatelain P, et al. Left ventricular assist device malfunction: an approach to diagnosis by echocardiography. J Am Coll Cardiol. 2005;45:1435-1440.
17. Paul S, Leacche M, Unic D, et al. Determinants of outcomes for postcardiotomy VAD placement: an 11-year, two-institution study. J Cardiac Surg. 2006;21:234-237.
18. Vranckx P. Clinical introduction of the TandemHeart, a percutaneous left ventricular assist device, for circulatory support during high-risk percutaneous coronary intervention. Int J Cardiovasc Interv. 2003;5(1):35-39.
19. Bonvini RF. High-risk left main coronary stenting supported by percutaneous left ventricular assist device. Catheter Cardiovasc Interv. 2005;66(2):209-212.
20. Thiele H, Lauer B, Hambrecht R, Boudriot E, Cohen HA, Schuler G. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation. 2001;104:2917-2922.
21. Gammie JS, Edwards LB, Griffith BP, Pierson RN, Tsao L. Optimal timing of cardiac transplantation after ventricular assist device implantation. J Thorac Cardiovasc Surg. 2004;127:1789-1799.
22. Butler J, Howser R, Portner PM, Pierson RN. Diabetes and outcomes after left ventricular assist device placement. J Cardiac Fail. 2005;11:510-515.
23. Butler J, Geisberg C, Howser R, et al. Relationship between renal function and left ventricular assist device use. Ann Thorac Surg. 2006;81:1745-1751.
24. Dang NC, Topkara VK, Kim BT, Lee BJ, Remoli R, Naka Y. Nutritional status in patients on left ventricular assist device support. J Throac Cardiovasc Surg. 2005;130:e3-e4.
25. Schenk S, McCarthy PM, Blackstone EH, et al. Duration of inotropic support after left ventricular assist device implantation: risk factors and impact on outcome. J Thorac Cardiovasc Surg. 2006;131:447-454.
26. Gonzalez-Stawinski GV, Atik FA, McCarthy PM, et al. Early and late rejection and HLA sensitization at the time of heart transplantation in patients bridged with left ventricular assist devices. Transplant Proc. 2005;37:1349-1351.
27. Baran DA, Gass AL, Galin ID, et al. Lack of sensitization and equivalent post-transplant outcomes with the Novacor left ventricular assist device. J Heart Lung Transplant. 2005;24:188-1890.
28. Kumpati GS, Cook DJ, Blackstone EH, et al. HLA sensitization in ventricular assist device recipients: does type of device make a difference? J Thorac Cardiovasc Surg. 2004;127:1800-1807.
29. Grinda JM, Bricourt MO, Amrein C, et al. Human leukocyte antigen sensitization in ventricular assist device recipients: a lesser risk with the DeBakey axial pump. Ann Thorac Surg. 2005;80:945-948.
30. Pamboukian SV, Costanzo MR, Dunlap S, et al. Relationship between bridging with ventricular assist device on rejection after heart transplantation. J Heart Lung Transplant. 2005;24:310-315.
31. Simon MA, Kormos RL, Gorscan J, et al. Differential exercise performance on ventricular assist device support. J Heart Lung Transplant. 2005;24:1506-1512.
32. Dandel M,Weng Y, Siniawski H, Potapov E, Lehmkuhl HB, Hetzer R. Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices. Circulation. 2005;112(suppl I):I-37-I-45.
33. Akgul A, Skrabal CA, Thompson LO, et al. Role of mast cells and their mediators in failing myocardium under mechanical ventricular support. J Heart Lung Transplant. 2004;23:709-715.
34. Akgul A, Youker KA, Noon GP, Loebe M. Quantitative changes in mast cell populations after left ventricular assist device implantation. ASAIO J. 2005;51:275-280.
35. Rodrigue-Wau A, Burkhoff D, Geesaman BJ, et al. Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support. J Heart Lung Transplant. 2005;24:73-80.
36. Wohlschlaeger J, Schmitz KJ, Schmid C, et al. Reverse remodeling following insertion of left ventricular assist devices (LVAD): a review of the morphological and molecular changes. Cardiovasc Res. 2005;68:376-386.
37. Patten RD, DeNofrio D, El-Zaru M, et al. Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart. J Am Coll Cardiol. 2005;45:1419-1424.
38. Dembitsky WP, Tector AJ, Park S, et al. Left ventricular assist device performance with long-term circulatory support: lessons from the REMATCH trial. Ann Thorac Surg. 2004;78:2123-2130.
39. Park SJ, Tector A, Piccioni W, et al. Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg. 2005;129:9-17.
40. Long JW, Kfoury AG, Slaughter MS, et al. Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. Congest Heart Fail. 2005;11:133-138.
41. DiGiorgi PL, Reel MS, Thornton B, Burton E, Naka Y, Oz MC. Heart transplant and left ventricular assist device costs. J Heart Lung Transplant. 2005;24:200-204.
42. Bramstedt KA, Nash PJ. When death is the outcome of informed refusal: dilemma of rejecting ventricular assist device therapy. J Heart Lung Transplant. 2005;24:229-230.
43. MacIver J, Ross HJ. Withdrawal of ventricular assist device support. J Palliat Care. 2005;21:151-156.